Live Breaking News & Updates on நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ஸ்டாக்‌ஹோல்ம்|Page 5

Stay updated with breaking news from நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ஸ்டாக்‌ஹோல்ம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Targinta recruits Per Norlén as CEO

2021-05-21 08:40
Xintela meddelar idag att bolaget har erhållit tillstånd från Läkemedelsverket att producera cellterapiprodukter, så kallade avancerade terapiläkemedel (ATMPs), i den egna GMP-anläggningen.
2021-05-21 08:40
Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility.
2021-05-20 11:40
Xintela tillkännager idag att bolaget ska utveckla sin stamcellsprodukt XSTEM® för behandling av svårläkta (kroniska) sår. I samarbete med Brännskadecentrum vid Universitetssjukhuset i Linköping har Xintela i en preklinisk sårmodell visat utmärkt sårläkningsförmåga med XSTEM och planerar nu för en klinisk studie på patienter med svårläkta sår. ....

Greg Batcheller , Sven Kili , Per Norl , Alligator Bioscience , Chief Scientific Officer , Nasdaq First North Growth Market Stockholm , Certified Adviser , Nasdaq First North Growth Market , Erik Penser Bank , ஸ்வெந் கிளி , முதலை உயிர் அறிவியல் , தலைமை அறிவியல் அதிகாரி , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ஸ்டாக்‌ஹோல்ம் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை , ஏறிக் பென்சர் வங்கி ,

Sweden – Wise Group announces offer for shareholders to acquire units in subsidiary Brilliant Future

Wise Group (WISE:SS), the Swedish staffing firm, announced that it is offering the shareholders in Wise to acquire units, consisting of shares and warrants, in its subsidiary Brilliant Future. ....

Wise Digital Hr Services , Wise Group , Daily Newsview All , Nasdaq First North Growth Market Stockholm , Nasdaq First North , Sweden Wise Group Announces Offer For Shareholders To Acquire Units In Subsidiary Brilliant Future , பாண்டித்தியம் குழு , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ஸ்டாக்‌ஹோல்ம் , நாஸ்டாக் முதல் வடக்கு ,

Embracer Group completes the acquisitions of Aspyr, Easybrain and Gearbox Entertainment

Embracer Group completes the acquisitions of Aspyr, Easybrain and Gearbox Entertainment
STOCKHOLM, April 6, 2021 /PRNewswire/
On February 3, 2021 Embracer Group AB (the Company or Embracer Group ) and its subsidiaries entered into agreements regarding the acquisition of Aspyr, Easybrain and Gearbox Entertainment, which was announced through press releases on February 3, 2021 (the Transactions ). The aggregated day one purchase price for the Transactions amounts to approximately SEK 9.3 billion in total, on a cash and debt free basis. Approximately SEK 2.5 billion is paid in cash and approximately SEK 6.8 billion is paid in newly issued B shares of the Company. A maximum additional consideration amounting to SEK 12.5 billion on an aggregated basis can be paid, subject to fulfilment of agreed financial and operational milestones, during a period of up to 7 years. The additional consideration comprises a maximum of approximately SEK 7.0 billion to be paid in cash and a ....

Dead Island , South Africa , Beatrice Forsgren , Lars Wingefors , Company Or Embracer Group , Embracer Group , Saber Interactive , Communication Embracer Group , Baker Mckenzie , Gearbox Entertainment , Nasdaq First North Growth Market , Saints Row , Goat Simulator , Koch Media , Deep Silver , Coffee Stain , Amplifier Game Invest , Nasdaq First North Growth Market Stockholm , Certified Adviser , இறந்தவர் தீவு , சபெற் ஊடாடும் , ரொட்டி சுடுபவர் மகெந்ஸீ , கியர்‌பாக்ஸ் பொழுதுபோக்கு , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை , புனிதர்கள் வரிசை , வெள்ளாடு சிமுலேட்டர் ,

Sivers Semiconductors Continues To Grow Number Of Design Wins

Sivers Semiconductors Continues To Grow Number Of Design Wins
Sivers Semiconductors AB today announces that the company has won new design wins with three new customers. The aim is to use Sivers Semiconductors’ technology in new products in new verticals/for new use cases as well as in products at customers with an existing product line in the millimeter wave area.
Sivers Wireless has previously communicated 21 design wins where customers have existing agreements or have ongoing design and development activities integrating Sivers Wireless RFICs or RF Modules into their products. Now, the number of design wins are 24.
The first of these three design wins is with a European listed technology company with approx. 8 billion SEK in yearly net sales, who will base their upcoming technology platform and service offering on Sivers Wireless 5G millimeter wave product, the TRX BF/02. This engagement may present future volume opportunities over time, but at this point in time ....

United States , Sivers Semiconductor , Sivers Semiconductors , Sivers Semiconductors Wireless , Sivers Wireless , Anders Storm , Nasdaq First North Growth Market Stockholm , Semiconductors Sivers Wireless , ஒன்றுபட்டது மாநிலங்களில் , சிவேர்ச் குறைக்கடத்தி , சிவேர்ச் குறைக்கடத்திகள் , சிவேர்ச் குறைக்கடத்திகள் வயர்லெஸ் , சிவேர்ச் வயர்லெஸ் , ஆண்டர்ஸ் புயல் , நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ஸ்டாக்‌ஹோல்ம் , குறைக்கடத்திகள் சிவேர்ச் வயர்லெஸ் ,

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
Allarity Therapeutics A/SMarch 9, 2021 GMT
- Treatment of animal osteosarcoma models with dovitinib increased the median survival time
by 50 % as compared to control animals.
Press release
Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive data from its preclinical assessment of dovitinib’s antitumor activity in osteosarcoma, the most common primary malignant bone tumor in children and young adults. The purpose of the study was to investigate the capacity of dovitinib alone, and in combination with a specific checkpoint inhibition strategy (anti-PD-1), for slowing the progression of experimental pulmonary metastases in animal models of osteosarcoma. ....

Marie Foegh , Steve Carchedi , Thomas Pedersen , Jens Knudsen , Carrotize Pr Communications , Allarity Therapeutics , Drug Response Predictor , Companion Diagnostic , Nasdaq First North Growth Market Stockholm , Corporate News , Products And Services , Covid 19 Pandemic , Product Testing , Clinical Trials , Pharmaceutical Manufacturing , Coronavirus Pandemic , Health Care Industry , Breast Cancer , Lung Disease , Diseases And Conditions , Infectious Diseases , Medical Research , Drug Trials , Globe Newswire , Government And Politics , Government Regulations ,